reports
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp 26-Apr-2024 / 14:51 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, th...
- Wedbush Research
DPZ DOMINO'S PIZZA INC.
SHAK SHAKE SHACK INC. CLASS A
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
VLY VALLEY NATIONAL BANCORP
TXRH TEXAS ROADHOUSE INC.
TSCO TRACTOR SUPPLY COMPANY
SKX SKECHERS U.S.A. INC. CLASS A
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MTH MERITAGE HOMES CORPORATION
MCD MCDONALD'S CORPORATION
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
FFWM FIRST FOUNDATION
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EWBC EAST WEST BANCORP INC.
EAT BRINKER INTERNATIONAL INC.
DENN DENNY'S CORPORATION
CUBI CUSTOMERS BANCORP INC.
CTMX CYTOMX THERAPEUTICS INC.
COLB COLUMBIA BANKING SYSTEM INC.
CMRX CHIMERIX INC
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BPMC BLUEPRINT MEDICINES CORP.
AXTI AXT INC.
BJRI BJ'S RESTAURANTS INC.
CFR CULLEN/FROST BANKERS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
SWTX SPRINGWORKS THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
RVMD IDEAYA BIOSCIENCES
BDTX REVOLUTION MEDICINES
ITOS BLACK DIAMOND THERAPEUTICS
ORIC ITEOS THERAPEUTICS
ZNTL ORIC PHARMACEUTICALS
BEAM ZENTALIS PHARMACEUTICALS
COGT BEAM THERAPEUTICS
IMNM COGENT BIOSCIENCES INC
VOR IMMUNOME
NUVB VOR BIOPHARMA
DAWN NUVATION BIO INC (A)
ELEV DAY ONE BIOPHARMACEUTICALS INC
FHTX ELEVATION ONCOLOGY
STX FOGHORN THERAPEUTICS
IKNA SEAGATE TECHNOLOGY HLDGS PLC
TCRX IKENA ONCOLOGY INC
HOWL TSCAN THERAPEUTICS INC
GLUE WEREWOLF THERAPEUTICS INC
GFS MONTE ROSA THERAPEUTICS INC
CMPX GLOBALFOUNDRIES INC
GMTX COMPASS THERAPEUTICS
JANX GEMINI THERAPEUTICS INC
TYRA JANUX THERAPEUTICS INC
HR TYRA BIOSCIENCES INC
NUVL HEALTHCARE TRUST OF AMERICA INC.
BOLD NUVALENT INC
AUDENTES THERAPEUTICS
- Michael Symington
- Nick Setyan
Cytokinetics Inc: 1 director
A director at Cytokinetics Inc sold 10,562 shares at 64.540USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corp 25-Apr-2024 / 14:27 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, th...
American Airlines Reports First-Quarter 2024 Financial Results
American Airlines Reports First-Quarter 2024 Financial Results FORT WORTH, Texas, April 25, 2024 (GLOBE NEWSWIRE) -- American Airlines Group Inc. (NASDAQ: AAL) today reported its first-quarter 2024 financial results, including: Record first-quarter revenue of approximately $12.6 billion.First-quarter net loss of $312 million, or ($0.48) per diluted share. Excluding net special items1, first-quarter net loss of $226 million, or ($0.34) per diluted share.Achieved best-ever first-quarter completion factor. Generated operating cash flow of $2.2 billion and free cash flow2 of $1.4 billion in ...
Pathward Financial, Inc. Announces Results for 2024 Fiscal Second Quar...
SIOUX FALLS, S.D.--(BUSINESS WIRE)-- Pathward Financial, Inc. (“Pathward Financial” or the “Company”) (Nasdaq: CASH) reported net income of $65.3 million, or $2.56 per share, for the three months ended March 31, 2024, compared to net income of $54.8 million, or $1.99 per share, for the three months ended March 31, 2023. For the fiscal quarter ended March 31, 2023, the Company recognized adjusted net income of $60.3 million, or $2.18 per share, when adjusting for the adverse financial impacts related to legacy mobile solar transactions and a venture capital investment impairment expense. See no...
Cytokinetics to Announce First Quarter Results on May 8, 2024
Cytokinetics to Announce First Quarter Results on May 8, 2024 SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinet...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 24-Apr-2024 / 13:58 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporat...
The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: Quanex Building Products Corporation 23-Apr-2024 / 13:59 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: The Vanguard Group, Inc. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a tr...
Innovative Industrial Properties to Report 2024 First Quarter Results
SAN DIEGO--(BUSINESS WIRE)-- Innovative Industrial Properties, Inc. (NYSE: IIPR) announced today it will report results for its first quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024. Alan Gold, Executive Chairman, Paul Smithers, President and Chief Executive Officer, David Smith, Chief Financial Officer, Catherine Hastings, Chief Operating Officer, and Ben Regin, Chief Investment Officer, will host an investor conference call at 10:00 a.m. Pacific Time on Thursday, May 9, 2024, to discuss the company’s financial results and operations for the quarter. The cal...
Quanex Building Products to Acquire Tyman, Creating a Comprehensive So...
Quanex Building Products to Acquire Tyman, Creating a Comprehensive Solutions Provider in the Building Products Industry Acquisition Accelerates Quanex’s “BIGGER” Strategic Roadmap, Expanding Quanex’s Product Offering with Addition of Tyman’s Complementary Portfolio Significantly Enhances Scale and Global Reach, Positioning Combined Company for Profitable Growth and Value Creation Delivers Material EPS Accretion in First Fiscal Year Post Close; Approximately $30 Million in Annual Run-Rate Cost Synergies Anticipated Investor Conference Call Scheduled for Today at 8:30 a.m. ET / 7:30...
SolarEdge Announces Compliance with the UK’s Cyber Security Regulatory...
MILPITAS, Calif.--(BUSINESS WIRE)-- , Inc. (“SolarEdge”) (NASDAQ: SEDG), a global leader in smart energy technology, today announced that its entire product portfolio complies with the UK’s Product Security and Telecommunications Infrastructure (PSTI) regulation, due to come into effect on April 29, 2024. This press release features multimedia. View the full release here: SolarEdge Home in the UK (Photo: Business Wire) The UK’s new PSTI regulatory scheme aims to make internet-connectable products more secure amid a growing awareness of cyber security threats. This requires all manufacturers o...
Pathward Financial, Inc. to Announce Second Quarter 2024 Earnings and ...
SIOUX FALLS, S.D.--(BUSINESS WIRE)-- Pathward Financial, Inc. (“Pathward Financial”, the “Company”) (Nasdaq: CASH) today announced it will release financial results for the second quarter of fiscal year 2024 on Wednesday, April 24, 2024, after market close. Pathward Financial will also host a conference call and earnings webcast with a corresponding presentation at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on the same day to discuss these results. The live webcast of the call can be accessed from Pathward Financial’s Investor Relations website at . Telephone participants may access the...
Cytokinetics Announces Three Late Breaking Clinical Trial Presentation...
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Clinical Trial presentations relating to SEQU...
First Solar Inc: 2 directors
Two Directors at First Solar Inc sold 4,337 shares at between 175.000USD and 176.000USD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Ope...
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in ...
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Ope...
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and Function SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in ...
SolarEdge Acquires Wevo Energy, EV Charging Optimization and Managemen...
MILPITAS, Calif.--(BUSINESS WIRE)-- , Inc. (“SolarEdge”) (NASDAQ: SEDG), a global leader in smart energy technology, today announced that it completed the acquisition of the entire share capital of Wevo Energy Ltd. (“Wevo”). Wevo is a software startup specializing in EV charging optimization and management for sites with large quantities of EV chargers such as apartment buildings, workplace carparks and public charging locations. This press release features multimedia. View the full release here: Illustration of EV Charging Interface (Photo: Business Wire) Wevo’s software is designed to be ve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.